Exploring rheumatoid arthritis associated interstitial lung disease a retrospective study from two Saudi tertiary care centers

Table 6 Treatments before and after the ILD diagnosis ⁽ⁿ⁼⁵⁴⁾

Medications	Before ILD Diagnosis N (%)	Post ILD diagnosis N (%)	P-value ^§
Prednisolone use	19 (35.8%)	18 (35.3%)	1.000
Methotrexate	27 (50.9%)	14 (28.0%)	0.002 **
Other csDMARDs	22 (41.5%)	25 (49.0%)	0.742
bDMARDs
• Anti-TNF	07 (13.0%)	09 (17.6%)	0.485
• Non-TNF	11 (20.8%)	10 (19.6%)	0.742
tsDMARDs	07 (13.0%)	14 (27.5%)	0.051
Rituximab	07 (13.0%)	10 (20.0%)	0.322
Cyclophosphamide	01 (01.9%)	--	--
Anti-fibrotic	--	04 (07.8%)	--

csDMARDs- conventional synthetic disease-modifying antirheumatic drugs; bDMARDs- biologic disease-modifying antirheumatic drugs; tsDMARDs- targeted synthetic disease-modifying antirheumatic drugs
^§P-value has been calculated using paired sample t-test
** Significant at p < 0.05 level

ISSN: 2520-1026